• English
    • Ελληνικά
    • Deutsch
    • français
    • italiano
    • español
  • italiano 
    • English
    • Ελληνικά
    • Deutsch
    • français
    • italiano
    • español
  • Login
Mostra Item 
  •   DSpace Home
  • Επιστημονικές Δημοσιεύσεις Μελών ΠΘ (ΕΔΠΘ)
  • Δημοσιεύσεις σε περιοδικά, συνέδρια, κεφάλαια βιβλίων κλπ.
  • Mostra Item
  •   DSpace Home
  • Επιστημονικές Δημοσιεύσεις Μελών ΠΘ (ΕΔΠΘ)
  • Δημοσιεύσεις σε περιοδικά, συνέδρια, κεφάλαια βιβλίων κλπ.
  • Mostra Item
JavaScript is disabled for your browser. Some features of this site may not work without it.
Tutto DSpace
  • Archivi & Collezioni
  • Data di pubblicazione
  • Autori
  • Titoli
  • Soggetti

Molecular diagnostic testing for primary biliary cholangitis

Thumbnail
Autore
Gatselis N.K., Dalekos G.N.
Data
2016
Language
en
DOI
10.1080/14737159.2016.1217159
Soggetto
antinuclear antibody
autoantibody
biological marker
microRNA
mitochondrion antibody
biological marker
microRNA
cholangitis
enzyme linked immunosorbent assay
epigenetics
genetic marker
human
immunoassay
immunoblotting
immunofluorescence
metabolomics
molecular diagnosis
multiplexed assay
nonhuman
primary biliary cholangitis
Review
Autoimmune Diseases
blood
genetics
liver failure
metabolism
procedures
trends
Autoimmune Diseases
Biomarkers
Cholangitis
Humans
Liver Failure
MicroRNAs
Molecular Diagnostic Techniques
Taylor and Francis Ltd
Mostra tutti i dati dell'item
Abstract
Introduction: A reliable liver autoimmune serology for the diagnosis of primary biliary cholangitis (PBC) is of particular importance. Recognition of patients at early stages and prompt treatment initiation may alter the outcome, slow progression, delays liver failure, and improves survival. Areas covered: In this review, we summarize and discuss the published data obtained from literature searches from PubMed and The National Library of Medicine (USA) and our own experience on the current and potential molecular based approaches to the diagnosis of PBC. Expert commentary: Standardization of liver diagnostic serology and clinical governance are two major points as antimitochondrial antibodies are the diagnostic hallmark of the disease and PBC-specific antinuclear antibodies could assist in the diagnosis and estimation of prognosis. New biomarkers such as novel autoantibodies, genetic polymorphisms, metabolomic profiling, micro-RNA and epigenetics may assist to the understanding, diagnosis and management of the disease. © 2016 Informa UK Limited, trading as Taylor & Francis Group.
URI
http://hdl.handle.net/11615/71989
Collections
  • Δημοσιεύσεις σε περιοδικά, συνέδρια, κεφάλαια βιβλίων κλπ. [19743]
htmlmap 

 

Ricerca

Tutto DSpaceArchivi & CollezioniData di pubblicazioneAutoriTitoliSoggettiQuesta CollezioneData di pubblicazioneAutoriTitoliSoggetti

My Account

LoginRegistrazione
Help Contact
DepositionAboutHelpContattaci
Choose LanguageTutto DSpace
EnglishΕλληνικά
htmlmap